In recent years, SEO (search engine optimization) services have gained popularity and many SEO companies or agencies have cropped up to offer SEO services in Malaysia.
There are also outright scams from "bad apples" in the industry that had led you to be disappointed. The popularity of Google search engine optimization (SEO) and number one ranking is one of the primary selling features.
You should learn more about Google SEO from Google. Get direct updates and credible information directly from Google itself. Free resources such as Google Search Console, the official Webmaster Central blog, and Google’s discussion forum can provide you with a great deal of information about how to optimize your site for organic search.
Best SEO Companies in Selangor
The selection of the SEO companies below is based on Google Search Results and information available on blogs and forums. The top SEO companies in Malaysia have been arranged in no particular order. Here is the list.
1. Locus - T Online Sdn Bhd
Website : https://www.locus-t.com.my/
Facebook : https://www.facebook.com/locustMY/
Whatsapp : +6017-300 2078
Address: 72, Jalan 17/22, Seksyen 17, 47400 Petaling Jaya, Selangor
LOCUS-T is an Internet Marketing Agency, a company that is packed with 18 years of Internet Marketing experience.
Highlights
- Eligible for BSN SME Grant, up to 50% or up to RM5000 waiver
- Google SEO (Search Engine Optimization), Google Ads, Facebook Ads and Website Design
- Served over 7000 MNCs and SMEs
- Over 20 years experience in web development and web design
Testimonials
Locus-T helped position my company well on Google, and brought in 700% ROI during the first month.Besides the great results, their team is responsive and attentive to changes needed month by month. I would recommend them if you want your company to have a competitive online presence.
Address : C-20-05, Level 20, Colonial Loft, Empire City, Jalan PJU 8/1, Damansara Perdana, 47820, Petaling Jaya, Selangor
What sets this company apart is the clarity and comprehensiveness of the entire process. You can expect little to no failures in their strategies, which will be based around the structure and missions of your business. Their service will be tailor fit and extensive, providing both on-site optimisation as well as copywriting to help you get ahead of your competition.
Services : SEO, Google Ads, Facebook Ads, Website Development, Video Production, Copywriting
Testimonial
Kempen Facebook Ads kami dapat return yang lebih tinggi bila Bomstart Media yang handle. Masa buat sendiri kami hanya boleh dapat ROAS sekitar 5 sahaja. Bila Bomstart buat, dapat ROAS sehingga 20. Bomstart Media terbaik.. 👍👍👍
Address: A-06-07, Prima Avenue, Jalan PJU 1/39, Dataran Prima, 47301 Petaling Jaya, Selangor
"You’re reading this because you found us on Google. We compete with some of the top SEO service providers in the country and yet we still outranked them. Besides, if you are not ranked on Google, your competitors will be and they will the be the ones that reach out to your customers. SEO is no longer a nice to have, it is a must have for any business or company. Imagine waking up with customers contacting you for your products or services, all day, everyday. We know how that feels like and it is amazing."
Highlights
- Google Rankings or the bears will work for free : Free if you don't show up on page 1 of Google within 90 days
- Over 700 projects completed
Testimonial
I chanced upon Bike Bear when I was Google searching for a website design company. Being a marketer, I was very meticulous about the quality of work. I didn't want mere designers to do the job, no matter how great their aesthetic sense may be... I wanted people who understood how their design and website development can help propel my business goals.
1 and a half years later, I'm glad to say I have found a reliable and strong partner. Their design is not only great, they also took the effort to support our business goals through strategic website development and marketing campaigns.
Till this day, I still find it amusing that I found them through a Google Search. Needless to say, their SEO team must have done something right.
Really grateful to have Ariel, Jason and their excellent team seeing us through numerous websites and marketing campaigns. Hey, they even won us an award through our official website.
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching ...
Here are the top 10 healthcare companies by revenue as of 2024-2025, primarily based on trailing twelve-month (TTM) and fiscal year 2024 revenue data from multiple sources: 1. UnitedHealth Group Inc. Revenue: Approximately $379.5 billion to $410 billion Description: A leading health insurance company providing data analytics, consulting, and pharmacy care services. Market: NYSE, USA ( 1 , 2 , 4 ) 2. CVS Health Corp. Revenue: Around $361 billion to $373 billion Description: A major pharmacy benefits manager and health services provider. Market: NYSE, USA ( 1 , 2 , 4 ) 3. McKesson Corp. Revenue: About $309 billion to $359 billion Description: A global pharmaceutical distribution and healthcare services company. Market: NYSE, USA ( 1 , 2 , 4 ) 4. Cencora (formerly AmerisourceBergen) Revenue: Approximately $294 billion to $310 billion Description: A pharmaceutical sourcing and distribution services company. Market: NYSE, USA ( 2 , 4 ) 5. Cardinal He...
Biopharma may soon be in for a blockbuster boom. In the latest edition of its annual ranking of the biggest potential drug launches of the coming year, Evaluate listed 10 drugs that are slated to earn approvals in 2025. According to the analysts’ forecasts, all together, the meds stand to generate a whopping $29 billion in annual sales by the end of the decade. That’s nearly double the estimate for last year’s top 10 . In that case, Evaluate calculated a conservative $15.2 billion in 2028 sales for 2024’s biggest expected launches, which included the likes of Bristol Myers Squibb’s schizophrenia drug Cobenfy , Eli Lilly’s Alzheimer’s disease med Kisunla and Madrigal Pharmaceuticals’ MASH treatment Rezdiffra in the top three—all of which were indeed approved throughout last year. In fact, 2025’s total is the highest in the last five years, topping even Evaluate’s high-flying forecast for 2022, when the analysts estimated total 2026 sales of $26.9 billion for the year’s most anti...
Here are the top 10 pharmaceutical companies by market cap as of July 2025. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com Lilly—boosted by...
Summary 1. Stelara: 2024 U.S. sales: $6.72 billion 2. Eylea: 2024 U.S. sales: $4.77 billion 3. Prolia/Xgeva: 2024 U.S. sales: $4.39 billion 4. Entresto: 2024 U.S. sales: $4.05 billion 5. Soliris: 2024 U.S. sales: $1.52 billion 6. Promacta: 2024 U.S. sales: $1.18 billion 7. Simponi/Simponi Aria: 2024 U.S. sales: $1.08 billion 8. Tysabri: 2024 U.S. sales: $920 million 9. Tasigna: 2024 U.S. sales: $848 million 10. Brilinta: 2024 U.S. sales: $751 million Introduction While the pharmaceutical industry routinely faces high-profile losses of exclusivity each year, this year's list is particularly notable. Johnson & Johnson’s Stelara is already contending with several biosimilars, with more expected throughout the year. With $6.72 billion in U.S. sales projected for 2024, Stelara represents the largest U.S. loss of exclusivity since AbbVie’s Humira patent cliff in early 2023. Although Johnson & Johnson had anticipated a “late 2023” patent expiration, the company extended Stelara’s ...
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
What's the difference between glutathione and NAD? We will cover the essentials and explain about each of these nutrients below. What is Glutathione? Glutathione or GSH (tripeptide of glutamic acid, cysteine, and glycine) is referred to as the body’s “master antioxidant” or the “mother of all antioxidants” because it is your body’s primary and most prevalent protector, found in all mammalian tissue. Types of Glutathione There is a lot of confusion about GSH and what makes an effective glutathione supplement. There are different types, different formulas, and a lot of different companies saying different things. L-Glutathione or Reduced Glutathione because it is the most commonly found, least expensive, and the true core behind other forms you will find. There is some debate whether L-Glutathione alone can be effective taken orally. The theory being the enzymes in your stomach break it down before it can ever reach the blood stream and become useful. Some evidence ...
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 10 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in its cap. With more than 30 indications across various cancer types and stages, the PD-L1 inhibitor shows no signs of stopping. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. N...
Comments